 SAN DIEGO, Sept. 07, 2021 GLOBE NEWSWIRE -- Crinetics Pharmaceuticals Nasdaq: CRNX, a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in the following investor conferences in the month of September: 